Brukinsa (zanubrutinib) — United Healthcare
Waldenström’s macroglobulinemia (WM)
Initial criteria
- Diagnosis of Waldenström’s macroglobulinemia (WM)
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Brukinsa therapy
Approval duration
12 months